(Q39400223)

11 September 2017

title

Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia. (English)

1 reference

Julianne Imperato-McGinley

11 September 2017

author

2

object named as

Imperato-McGinley J

1 reference

11 September 2017

Vaughan D

1

1 reference

11 September 2017

McConnell J

3

1 reference

11 September 2017

Matsumoto AM

4

1 reference

11 September 2017

Bracken B

5

1 reference

11 September 2017

Roy J

6

1 reference

11 September 2017

Sullivan M

7

1 reference

11 September 2017

Pappas F

8

1 reference

11 September 2017

Cook T

9

1 reference

11 September 2017

Daurio C

10

1 reference

11 September 2017

Meehan A

11

1 reference

11 September 2017

Stoner E

12

1 reference

11 September 2017

Waldstreicher J

13

1 reference

11 September 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

11 September 2017

1 reference

11 September 2017

volume

60

1 reference

11 September 2017

issue

6

1 reference

11 September 2017

page(s)

1040-1044

1 reference

The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901971-4

7 January 2021

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901971-4

7 January 2021

Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901971-4

7 January 2021

Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901971-4

7 January 2021

Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901971-4

7 January 2021

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901971-4

7 January 2021

Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901971-4

7 January 2021

Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901971-4

7 January 2021

Validation of a symptoms questionnaire for benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901971-4

7 January 2021

Maximum efficacy of finasteride is obtained within 6 months and maintained over 6 years. Follow-up of the Scandinavian Open-Extension Study. The Scandinavian Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901971-4

7 January 2021

Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901971-4

7 January 2021

Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901971-4

7 January 2021

10.1016/S0090-4295(02)01971-4

Identifiers

DOI

1 reference

11 September 2017

1 reference